Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 12/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 10/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430983 | 1.00 | CA2 (0.59) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1383106 | 1.00 | CA2 (0.59) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL3487482 | 0.98 | CA2 (0.57) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL6085529 | 0.98 | CA2 (0.57) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Bicarbonate SCHEMBL6086499 | 0.92 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7393368 | 0.89 | CA2 (0.49) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Maleic Acid SCHEMBL6086191 | 0.87 | CA2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Fumaric Acid SCHEMBL6086194 | 0.87 | CA2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL407503 | 0.86 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4936349 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | claimed |
| EP-1123933-A1 | 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent | MERCK PATENT GmbH (DE) | 2001-08-16 | — | — | EP | claimed |
| US-7045629-B2 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2006-05-16 | — | — | US | disclosed |
| EP-1383763-B1 | METHOD FOR PRODUCING 2-(-5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL)-CHROMANE | MERCK PATENT GMBH (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-1383763-A2 | METHOD FOR PRODUCING 2- -5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMANE | MERCK PATENT GmbH (DE) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002088117-A2 | METHOD FOR PRODUCING 2-[-5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMANE | MERCK PATENT GMBH (DE) | 2002-11-07 | — | — | WO | disclosed |
| EP-1123933-A1 | 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent | MERCK PATENT GmbH (DE) | 2001-08-16 | — | — | EP | disclosed |
| US-5767132-A | CENTRAL NERVOUS SYSTEM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-06-16 | — | — | US | disclosed |
| US-5703115-A | VASOCONSTRICTORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1997-12-30 | — | — | US | disclosed |
| US-5688952-A | VASOCONSTRICTOR INTERMEDIATES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1997-11-18 | — | — | US | disclosed |
| US-5624952-A | VASOCONSTRICTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-04-29 | — | — | US | disclosed |
| US-5607949-A | VASOCONTRICTORS, TREATING MIGRAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-04 | — | — | US | disclosed |
| US-5541180-A | HEADACHE THERAPY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-07-30 | — | — | US | disclosed |
| EP-0639192-B1 | (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN)-ALKYLAMINO] ALKYL SUBSTITUTED GUANIDINES AS SELECTIVE VASCOCONSTRICTORS | JANSSEN PHARMACEUTICA NV (BE) | 1996-05-15 | — | — | EP | disclosed |
| EP-0707007-A1 | Amino(thio)ether derivatives as CNS active agents | MERCK PATENT GmbH (DE) | 1996-04-17 | — | — | EP | disclosed |
| EP-0639192-A1 | (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN)-ALKYLAMINO] ALKYL SUBSTITUTED GUANIDINES AS SELECTIVE VASCOCONSTRICTORS. | JANSSEN PHARMACEUTICA NV (BE) | 1995-02-22 | — | — | EP | disclosed |
| WO-1993017017-A1 | [(BENZODIOXAN, BENZOFURAN OR BENZOPYRAN)-ALKYLAMINO] ALKYL SUBSTITUTED GUANIDINES AS SELECTIVE VASCOCONSTRICTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | PAH, HPD, CYP3A43 | CA2 28/4885HTR1A 227/4885SIGMAR1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.